Current Rating Overview
On 11 August 2025, MarketsMOJO revised Suraksha Diagnostic Ltd’s rating from 'Sell' to 'Hold', reflecting an improvement in the company’s overall mojo score from 42 to 52. This 'Hold' rating indicates a neutral stance, suggesting that investors should neither aggressively buy nor sell the stock at present but rather monitor its developments closely. The rating is based on a balanced assessment of four key parameters: Quality, Valuation, Financial Trend, and Technicals.
Quality Assessment
As of 31 December 2025, Suraksha Diagnostic Ltd demonstrates a good quality grade. The company’s ability to service its debt remains strong, with a low Debt to EBITDA ratio of 0.87 times, indicating manageable leverage and financial stability. Additionally, the company has shown robust long-term growth, with operating profit expanding at an annual rate of 89.29%. This growth trajectory highlights operational efficiency and effective management strategies within the healthcare services sector.
Valuation Perspective
The valuation grade for Suraksha Diagnostic Ltd is currently assessed as fair. The company’s Return on Capital Employed (ROCE) stands at 15.8%, which is a reasonable return relative to its capital base. The Enterprise Value to Capital Employed ratio is 4.8, suggesting that the stock is priced moderately in relation to the company’s capital utilisation. While the stock has experienced a negative return of -28.81% year-to-date, its profits have risen by 34% over the same period, indicating a disconnect between market pricing and underlying earnings growth.
Financial Trend Analysis
The financial trend for Suraksha Diagnostic Ltd is currently flat. The latest half-year results show some mixed signals: interest expenses have increased by 35.64% to ₹5.48 crores, and the operating profit to interest coverage ratio has declined to 8.67 times, the lowest in recent quarters. The debt-equity ratio has risen to 0.51 times, the highest level recorded in the half-year period. These factors suggest some pressure on the company’s financials, although the overall debt servicing capability remains adequate.
Technical Outlook
From a technical standpoint, the stock is exhibiting a sideways trend. Price movements over the past year have been subdued, with the stock delivering a negative return of -28.81% year-to-date and underperforming the BSE500 index over the last three years, one year, and three months. Shorter-term price action also reflects weakness, with declines of 9.00% over the past month and 10.12% over three months. This sideways technical grade suggests limited momentum and a lack of clear directional bias in the stock’s price.
Register here to know the latest call on Suraksha Diagnostic Ltd
- - Fundamental Analysis
- - Technical Signals
- - Peer Comparison
Stock Performance and Market Position
As of 31 December 2025, Suraksha Diagnostic Ltd is classified as a small-cap company within the healthcare services sector. The stock’s market performance has been challenging, with a year-to-date return of -28.81% and a one-year return mirroring this decline. Over the last six months, the stock has fallen by 18.55%, and the one-month performance shows a 9.00% drop. Despite these negative returns, the company’s operating profit growth of 89.29% annually and a 34% increase in profits over the past year highlight a fundamental strength that is yet to be fully reflected in the share price.
Institutional Interest and Investor Confidence
Institutional investors hold a significant stake in Suraksha Diagnostic Ltd, with 35.7% of shares owned by these entities. This level of institutional holding is noteworthy as such investors typically possess greater analytical resources and expertise to evaluate company fundamentals. Their continued investment suggests a degree of confidence in the company’s long-term prospects, despite recent share price volatility.
Balancing Risks and Opportunities
While Suraksha Diagnostic Ltd’s fundamentals show promise, the stock’s recent underperformance relative to broader market indices such as the BSE500 indicates caution. The company’s flat financial trend and sideways technical pattern imply that investors should carefully weigh the risks of further price declines against the potential for recovery driven by improving earnings and operational metrics.
Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!
- - Reliable Performer certified
- - Consistent execution proven
- - Large Cap safety pick
What the Hold Rating Means for Investors
The 'Hold' rating assigned to Suraksha Diagnostic Ltd by MarketsMOJO suggests that investors should maintain their current positions without initiating new purchases or sales. This rating reflects a balanced view where the company’s solid quality and fair valuation are offset by flat financial trends and sideways technical signals. Investors are advised to monitor upcoming quarterly results and market developments closely, as any significant improvement in financial trends or technical momentum could warrant a reassessment of the stock’s outlook.
Conclusion
In summary, Suraksha Diagnostic Ltd’s current 'Hold' rating is justified by a combination of good quality fundamentals, fair valuation metrics, flat financial trends, and sideways technical patterns as of 31 December 2025. While the stock has faced headwinds in terms of price performance, the company’s operational growth and institutional backing provide a foundation for potential recovery. Investors should consider this rating as a signal to observe the stock carefully and evaluate future developments before making significant portfolio changes.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →
